期刊文献+

普罗布考对早期糖尿病肾病患者血脂和炎性细胞因子hs-CRP、IL-1、IL-6水平的影响研究 被引量:1

Effects of Probucol on Patients'Serum hs-CRP,IL-1 and Inflammatory factor IL-6 with Early-stage Diabetic Nephropathy
下载PDF
导出
摘要 目的:探讨普罗布考影响早期糖尿病肾病患者血清hs-CRP和炎性细胞因子IL-1、IL-6水平。方法:将104例早期糖尿病肾病患者随机分为实验组与对照组,实验组除了常规治疗外还加用了普罗布考(500mg/次,BID),治疗8周,对照组仅给予常规治疗,比较两组不同的处理前后的hs-CRP、IL-1、IL-6、空腹血糖、血压、24小时尿微量白蛋白排泄率、低密度脂蛋白、高密度脂蛋白、血清总胆固醇、甘油三脂的高低。结果:治疗前两组的hs-CRP、IL-1、IL-6、空腹血糖、血压、24小时尿微量白蛋白排泄率、低密度脂蛋白、高密度脂蛋白、血清总胆固醇、甘油三脂比较,差异无统计学意义(P>0.05),经过不同处理,8周后,实验组血清hs-CRP、IL-1、IL-6和24小时尿微量白蛋白排泄率明显降低,与对照组比较差异有统计学意义(P<0.05);实验组血清低密度脂蛋白、高密度脂蛋白、血清总胆固醇和甘油三脂水平改善程度明显优于对照组,差异有统计学意义(P<0.05)。但两组空腹血糖和血压差异无统计学意义(P>0.05)。结论:普罗布考治疗早期糖尿病肾病的疗效显著,不仅能降低血脂,还起到降低早期糖尿病肾病患者血清中的hs-CRP、IL-1、IL-6水平,从而达到保护肾功能免受损害的作用。 Objective:To research the effects of probucol on patients' serum hs-CRP,IL-1 ,andIL-6 with early-stage diabetic nephropathy. Methods:104patients with early-stage DN were randomly divided into two groups,on the basis of conventional treatment,one group is blank control group and the other is experimental group, blank control group only received conventional treatment, experimental group received conventional treatment and Probucol (500mg/once, BID), After 8 weeks, to compare the hs- CRP,IL-l,IL-6,fasting blood glucose,blood pressure,UAER,LDL-C,HDL-C,TC,TG in the two group before and after the treatment. Result There were no significant differences in the levels of hs-CRP,IL-l,IL-6,fasting blood glucose,blood pressure, UAER, LDL-C, HDL-C, TC, TG between the two group before the treatment (P〉0.05), After 8 weeks, with different treatments, in the blank control group,there were no significant changer in the levels of hs-CRP,IL-l,IL-6,fasting blood glucose,blood pressure, UAER, LDL-C, HDL-C, TC, TG (P〉0.05), but in the experimental group, the levels of hs-CRP, IL-1, IL-6, UAER, LDL-C, HDL-C, TC,TG declined sharply (P〈0.05).Conclusion:There were no significant differences in the levels of the fasting blood glucose and blood pressure between the blank control group and the experimental group,But Probucol can not only decrease the level of blood- lipid,but also decrease the serum hs-CRP,IL-1 ,andlL-6 in the patients with early-stage DN,in this way,it could protect the kidney from damaging.
出处 《北方药学》 2013年第7期97-98,共2页 Journal of North Pharmacy
关键词 普罗布考 糖尿病肾病 HS-CRP 炎性因子 Probucol Diabetic nephropathy Hs-CRP Inflammatory factor
  • 相关文献

参考文献7

  • 1Mogensen CE, Schmitz A, Christensen CK. Comparative renal pathophysi -ology relevant to IDDM and NIDDM Patients[J].Di- abetes Metab Rev, 1988,4(5) :453-483.
  • 2Leinonen E,Hurt - Camejo E,Wiklund O,et al.Insulin resis- tance and adi-posity correlate with acute - phase reaction and soluble cell adhesion molecules in type 2 diabetes[J].Atheroscle- rosis, 2003,166(2) : 387-394.
  • 3Shikano M, Sobajima H, Yoshikawa H, et al. Usefulness of a highly sen-sitive urinary and serum IL-6 assay in patients with diabetic nephropathy[J].Nephron, 2000,85 ( 1 ) : 81-85.
  • 4Verma S, Li SH, Badiwala MV, et al.Endothelin antagonism and inter - leukin-6 inhibition attenuate the proatherogenic ef- fects of C-reactive protein [J].Cirulation, 2002,105 (16) : 1 890- 1896.
  • 5Devaraj S, Davis B, Simon SI, et al.CRP promotes mono- cyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions [J]. Am J Physiol Heart C irc Physiol, 2006,291 (3) : 1170-1176.
  • 6Devaraj S,Xu DY,Jialal I.C-reactive protein increases plas- minogen activator inhibitor - 1 expression and activity in human arotic endothelial cells:Implications for the metabolic syndrome and atherothrombosis [J].Circulation, 2003,107(3 ) : 398-404.
  • 7罗秀忠.阿托伐他汀联合普罗布考治疗狭窄性颈动脉粥样硬化斑块的疗效观察[J].中国现代医生,2010,48(11):147-148. 被引量:8

二级参考文献5

共引文献7

同被引文献12

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部